Literature DB >> 20018934

Pathways by which reconstituted high-density lipoprotein mobilizes free cholesterol from whole body and from macrophages.

Marina Cuchel1, Sissel Lund-Katz, Margarita de la Llera-Moya, John S Millar, David Chang, Ilia Fuki, George H Rothblat, Michael C Phillips, Daniel J Rader.   

Abstract

OBJECTIVE: Reconstituted high-density lipoprotein (rHDL) is of interest as a potential novel therapy for atherosclerosis because of its ability to promote free cholesterol (FC) mobilization after intravenous administration. We performed studies to identify the underlying molecular mechanisms by which rHDL promote FC mobilization from whole body in vivo and macrophages in vitro. METHODS AND
RESULTS: Wild-type (WT), SR-BI knockout (KO), ABCA1 KO, and ABCG1 KO mice received either rHDL or phosphate-buffered saline intravenously. Blood was drawn before and at several time points after injection for apolipoprotein A-I, phosphatidylcholine, and FC measurement. In WT mice, serum FC peaked at 20 minutes and rapidly returned toward baseline levels by 24 hours. Unexpectedly, ABCA1 KO and ABCG1 KO mice did not differ from WT mice regarding the kinetics of FC mobilization. In contrast, in SR-BI KO mice the increase in FC level at 20 minutes was only 10% of that in control mice (P<0.01). Bone marrow-derived macrophages from WT, SR-BI O, ABCA1 KO, and ABCG1 KO mice were incubated in vitro with rHDL and cholesterol efflux was determined. Efflux from SR-BI KO and ABCA1 KO macrophages was not different from WT macrophages. In contrast, efflux from ABCG1 KO macrophages was approximately 50% lower as compared with WT macrophages (P<0.001).
CONCLUSIONS: The bulk mobilization of FC observed in circulation after rHDL administration is primarily mediated by SR-BI. However, cholesterol mobilization from macrophages to rHDL is primarily mediated by ABCG1.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20018934      PMCID: PMC2842952          DOI: 10.1161/ATVBAHA.109.196105

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  39 in total

Review 1.  WinSAAM: a windows-based compartmental modeling system.

Authors:  Darko Stefanovski; Peter J Moate; Raymond C Boston
Journal:  Metabolism       Date:  2003-09       Impact factor: 8.694

2.  Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans.

Authors:  M N Nanjee; C J Cooke; R Garvin; F Semeria; G Lewis; W L Olszewski; N E Miller
Journal:  J Lipid Res       Date:  2001-10       Impact factor: 5.922

3.  High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization.

Authors:  P K Shah; J Yano; O Reyes; K Y Chyu; S Kaul; C L Bisgaier; S Drake; B Cercek
Journal:  Circulation       Date:  2001-06-26       Impact factor: 29.690

4.  Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1.

Authors:  N Wang; D L Silver; P Costet; A R Tall
Journal:  J Biol Chem       Date:  2000-10-20       Impact factor: 5.157

5.  High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI.

Authors:  P G Yancey; M de la Llera-Moya; S Swarnakar; P Monzo; S M Klein; M A Connelly; W J Johnson; D L Williams; G H Rothblat
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

Review 6.  Importance of different pathways of cellular cholesterol efflux.

Authors:  Patricia G Yancey; Anna E Bortnick; Ginny Kellner-Weibel; Margarita de la Llera-Moya; Michael C Phillips; George H Rothblat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-01-23       Impact factor: 8.311

Review 7.  The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues.

Authors:  Attilio Rigotti; Helena E Miettinen; Monty Krieger
Journal:  Endocr Rev       Date:  2003-06       Impact factor: 19.871

8.  Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on LCAT, PLTP, and CETP in plasma and peripheral lymph in humans.

Authors:  Takeshi Kujiraoka; M Nazeem Nanjee; Tomoichiro Oka; Mayumi Ito; Makoto Nagano; C Justin Cooke; Sadao Takahashi; Waldemar L Olszewski; Jinny S Wong; Irina P Stepanova; Robert L Hamilton; Tohru Egashira; Hiroaki Hattori; Norman E Miller
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-07-31       Impact factor: 8.311

9.  Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells.

Authors:  Scott D Covey; Monty Krieger; Wei Wang; Marsha Penman; Bernardo L Trigatti
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-06-26       Impact factor: 8.311

10.  Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein E-deficient mice.

Authors:  Wenwu Zhang; Patricia G Yancey; Yan Ru Su; Vladimir R Babaev; Yuomin Zhang; Sergio Fazio; MacRae F Linton
Journal:  Circulation       Date:  2003-10-27       Impact factor: 29.690

View more
  19 in total

Review 1.  Cardioprotective functions of HDLs.

Authors:  Kerry-Anne Rye; Philip J Barter
Journal:  J Lipid Res       Date:  2013-06-27       Impact factor: 5.922

2.  Cholesterol Accumulation in Dendritic Cells Links the Inflammasome to Acquired Immunity.

Authors:  Marit Westerterp; Emmanuel L Gautier; Anjali Ganda; Matthew M Molusky; Wei Wang; Panagiotis Fotakis; Nan Wang; Gwendalyn J Randolph; Vivette D D'Agati; Laurent Yvan-Charvet; Alan R Tall
Journal:  Cell Metab       Date:  2017-05-04       Impact factor: 27.287

Review 3.  Update on HDL receptors and cellular cholesterol transport.

Authors:  Ginny Kellner-Weibel; Margarita de la Llera-Moya
Journal:  Curr Atheroscler Rep       Date:  2011-06       Impact factor: 5.113

Review 4.  Role of ABC transporters in lipid transport and human disease.

Authors:  Elizabeth J Tarling; Thomas Q de Aguiar Vallim; Peter A Edwards
Journal:  Trends Endocrinol Metab       Date:  2013-02-14       Impact factor: 12.015

5.  Dyslipidemic diabetic serum increases lipid accumulation and expression of stearoyl-CoA desaturase in human macrophages.

Authors:  Bruce X W Wong; Reece A Kyle; Paul C Myhill; Kevin D Croft; Carmel M Quinn; Wendy Jessup; Bu B Yeap
Journal:  Lipids       Date:  2011-06-15       Impact factor: 1.880

6.  Influence of route of administration and lipidation of apolipoprotein A-I peptide on pharmacokinetics and cholesterol mobilization.

Authors:  Jie Tang; Dan Li; Lindsey Drake; Wenmin Yuan; Sara Deschaine; Emily E Morin; Rose Ackermann; Karl Olsen; David E Smith; Anna Schwendeman
Journal:  J Lipid Res       Date:  2016-11-23       Impact factor: 5.922

7.  Procollagen C-endopeptidase Enhancer Protein 2 (PCPE2) Reduces Atherosclerosis in Mice by Enhancing Scavenger Receptor Class B1 (SR-BI)-mediated High-density Lipoprotein (HDL)-Cholesteryl Ester Uptake.

Authors:  Ricquita D Pollard; Christopher N Blesso; Manal Zabalawi; Brian Fulp; Mark Gerelus; Xuewei Zhu; Erica W Lyons; Nebil Nuradin; Omar L Francone; Xiang-An Li; Daisy Sahoo; Michael J Thomas; Mary G Sorci-Thomas
Journal:  J Biol Chem       Date:  2015-05-06       Impact factor: 5.157

Review 8.  Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis.

Authors:  Jonathan D Smith
Journal:  Curr Opin Investig Drugs       Date:  2010-09

Review 9.  The ABCG family of membrane-associated transporters: you don't have to be big to be mighty.

Authors:  Ian D Kerr; Ameena J Haider; Ingrid C Gelissen
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

Review 10.  High-density lipoprotein function, dysfunction, and reverse cholesterol transport.

Authors:  Edward A Fisher; Jonathan E Feig; Bernd Hewing; Stanley L Hazen; Jonathan D Smith
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-12       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.